<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466073</url>
  </required_header>
  <id_info>
    <org_study_id>BTI-201</org_study_id>
    <nct_id>NCT03466073</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAegis Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAegis Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the
      Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin
      (rhu-pGSN) Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired
      Pneumonia (CAP)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 32 patients hospitalized with CAP will be randomized sequentially into 4 ascending
      dosing levels. Each dosing cohort will include 8 subjects randomized 3:1 rhu-pGSN:placebo (6
      rhu-pGSN subjects:2 placebo subjects). Patient, caregiver, and sponsor will be blinded to
      treatment. An unblinded pharmacist will prepare the infusion, but otherwise have no contact
      with subject.

      Dose will be based on actual body weight. Dose escalation will involve 3 dose levels of
      rhu-pGSN (6, 12, and 24 mg/kg) in patients admitted for CAP. Dose escalation will only occur
      after post-therapy safety information on all subjects in the prior cohort has been reviewed
      at Day 7 for the single-dose [SD] and multiple-ascending dose [MAD] arms. The MAD portion of
      the study will commence once single doses of 6 mg/kg of rhu-pGSN are shown to be acceptably
      safe. The first 2 doses must be administered in the hospital, but the third dose can be given
      in a monitored outpatient setting where appropriate. Discharged subjects will return for
      follow-up 7 days after the initiation of therapy (Day 7) and on Day 28 for the End-of-Study
      Visit.

      To assess safety and tolerability starting at the initiation of study therapy, subjects will
      undergo physical examinations (PE; including vital sign measurements), adverse event (AE)
      assessments, concomitant medication assessments, safety laboratory testing, and
      electrocardiograms (EKG) completed locally, and other testing as per local custom.

      Once informed consent is obtained, the following procedures will be performed:

        1. Randomize to currently enrolling treatment arm.

        2. Perform PE and document radiographic evidence of pneumonia if not previously completed
           in preceding 36 hours; calculate Confusion, Urea &gt;7 mmol/L, Respiratory rate ≥30/min,
           Blood pressure systolic &lt;90 or diastolic ≤60, and age ≥65 years (CURB-65), Sequential
           Organ Failure Assessment (SOFA), and Pneumonia Severity Index (PSI) scores.

        3. Obtain blood and sputum cultures, routine/standard labs, and EKG per standard of care
           (SOC) (if not already performed). The microbiology lab is encouraged to also perform
           sputum Gram-stains, antigen detection, immunoassay, and genomic diagnostic tests when
           available.

        4. Draw blood for baseline pGSN levels, C-reactive protein (CRP), procalcitonin level, and
           10 ml aliquot to be frozen for subsequent biomarker assays.

      Screening laboratory and other tests can serve as baseline values for participants (no need
      to repeat lab tests at entry if done within the prior 36 hours unless dictated by SOC).

      Obtain repeat chest x-rays (CXRs), computed tomography (CT) scans, and labs/cultures, etc.
      during the hospitalization if/when indicated by SOC.

      Recalculate CURB-65 and ΔSOFA scores and redraw procalcitonin, pGSN, and biomarker samples on
      Day 3 or 4 and Day 7.

      For the one dose in the SD arm and the first 2 doses in the multiple-dose arms, blood will be
      drawn within 30 minutes predose, immediately postdose, and 2, 8, 12 and/or 16, and 24 hours
      (± 30 minutes) after the end of infusion for analysis of plasma for maximum concentration
      (Cmax), time to maximum concentration (Tmax), terminal half-life (T1/2), area under the curve
      from time zero to 8 hours (AUC0-8), and area under the curve from time zero to infinity
      (AUCinf). Sampling at both the 12- and 16-hour time points is encouraged where feasible, but
      only one of these two times is required. Identical PK sampling is encouraged where feasible,
      but not required for the third (last) dose.

      On Day 28, collect samples for analysis of pGSN levels and antibodies against pGSN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>visibly indistinguishable therapy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>0-28 days</time_frame>
    <description>Treatment emergent adverse events were all adverse events (AEs) that occurred subsequent to enrollment. The seriousness of adverse events was judged by the site investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) (Area Under the Rhu-pGSN Concentration - Time Curve)</measure>
    <time_frame>On Days 0-3, specimens were obtained just prior and immediately post dose and 2, 8,12 and/or 16 , and 24 hours post completion of IV administration. In the single-dose arm, only 1 dose was given and thus no data from later days were obtained.</time_frame>
    <description>Determine AUC 0-t area under the plasma concentration-time curve of rhu-pGSN from 0-24 hours on dosing days (estimated by subtracting pre-injection concentrations from the measured concentrations at each time point). In the single-dose arm, the subject was given only 1 dose so that data from later days were not obtained. In the multiple-dose arms, samples were obtained for each of the 3 doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) (Maximum Observed Rhu-pGSN Plasma Concentration (Cmax))</measure>
    <time_frame>On Days 0-3, specimens were obtained just prior and immediately post dose and 2, 8, 12 and/or 16, and 24 hours post completion of IV administration. In the single-dose arm, only 1 dose was given and thus no data from later days were obtained.</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of rhu-pGSN in a 24 hours period after intravenous administration (estimated by subtracting pre-injection concentrations from the measured concentrations at each time point). For the 6 mg/kg dose, there were 4 evaluable subjects in the single-dose arm and 6 subjects in the multiple-dose arm at this dose, for a total of 10 evaluable subjects for Dose 1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Anti-pGSN Antibodies (Immunogenicity) at the End of Study (Day 28)</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of participants who developed antibodies against pGSN at study day 28. Patients were first tested against less stringent screening criteria: if screen-positive, a stricter confirmatory test was performed; if screen-negative, no further immunogenicity testing was done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline and Sequential Severity Scores</measure>
    <time_frame>Days 0-28</time_frame>
    <description>CURB-65 (a 5 point score in which 1 point is allocated to the presence of each of the following: Confusion, Urea &gt;7 mmol/L, Respiratory rate ≥30 breaths min, Blood pressure systolic &lt;90 mmHg or diastolic ≤60 mmHg, and age ≥65 years); PSI (Pneumonia Severity Index, used to predict risk of morbidity and mortality and is classified in risk classes ranging from I to V from the lowest to highest risk as follows: Class I: PSI 0, class II: PSI 1-70, class III: PSI 71-90, class IV: PSI 91-130, class V: PSI &gt;130); SOFA (Sequential Organ Failure Assessment, measured based on 6 variables each representing an organ system scored from 0 to 4 each (normal to severe organ dysfunction/failure), and reported as the sum (range 0-24))</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Single Dose 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose 12 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose 24 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Plasma Gelsolin</intervention_name>
    <description>Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water</description>
    <arm_group_label>Multiple Dose 12 mg/kg</arm_group_label>
    <arm_group_label>Multiple Dose 24 mg/kg</arm_group_label>
    <arm_group_label>Multiple Dose 6 mg/kg</arm_group_label>
    <arm_group_label>Single Dose 6 mg/kg</arm_group_label>
    <other_name>rhu-pGSN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline Placebo</intervention_name>
    <description>Normal saline in volume equivalent to drug</description>
    <arm_group_label>Multiple Dose 12 mg/kg</arm_group_label>
    <arm_group_label>Multiple Dose 24 mg/kg</arm_group_label>
    <arm_group_label>Multiple Dose 6 mg/kg</arm_group_label>
    <arm_group_label>Single Dose 6 mg/kg</arm_group_label>
    <other_name>NSS (0.9% normal saline)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent obtained from subject

          2. Domicile: home, assisted living, rehabilitation facility, or nursing home (as long as
             the prospective participant is capable of providing written informed consent)

          3. Duration of infection precipitating hospitalization by history &lt;14 days

          4. Planned or actual admission to hospital with a primary diagnosis of CAP within 24
             hours of presentation to the hospital

          5. Primary admitting diagnosis of pneumonia supported by a compatible clinical
             presentation with a documented infiltrate consistent with pneumonia on chest
             radiograph or CT, as assessed by the admitting emergency-department (ED), clinic, or
             ward physician or equivalent caregiver

               -  Recommended (not mandatory) guidance/discretionary criteria defining patients
                  with CAP:

                    -  At least 2 symptoms: difficulty breathing, cough, production of purulent
                       sputum, chest pain

                    -  At least 2 vital sign abnormalities: fever, tachycardia, tachypnea

                    -  At least one finding of other clinical signs and laboratory abnormalities:
                       hypoxemia, clinical evidence of pulmonary consolidation, an elevated total
                       white blood cell (WBC) count or leukopenia

                    -  Chest imaging showing new (or presumed new or worsening) infiltrates

               -  Receipt of antibiotic treatment prior to presentation does not exclude the
                  patient

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Intubation, vasopressor support, or admission to the intensive care unit (ICU)
             directly from the ED/office (fluids for responsive hypotension is not a reason for
             exclusion)

          3. Use of any investigational drug in the past 30 days

          4. Hospitalization during the last 30 days

          5. Residence within the last 30 days in long-term care facility where the patient remains
             persistently unable to participate in the routine activities of daily living

          6. Active underlying cancer treated with systemic chemotherapy or radiation therapy
             during the last 30 days

          7. Known or suspected immunosuppressive disease or therapy (including steroid use
             equivalent to prednisone ≥20 mg/day for &gt;7 days or known advanced human
             immunodeficiency virus (HIV) infection with CD4 count ≤200/mm3; specific testing for
             HIV status or CD4 count is not required but can be done at the discretion of the
             caregivers)

          8. Active congestive heart failure, myocardial infarction, or pulmonary embolism;
             cardiopulmonary arrest in last 30 days

          9. Weight &gt;100 kg

         10. Otherwise unsuitable for study participation in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J DiNubile, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BioAegis Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Geo Hospitals, Mtskheta Multiprofile Medical Center</name>
      <address>
        <city>Mtskheta</city>
        <zip>3300</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Rustavi Central Hospital</name>
      <address>
        <city>Rustavi</city>
        <zip>3700</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Central University Clinic After Academic N. Kipshidze</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD S. Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD 5th Clinical Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0191</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Georgia</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <results_first_submitted>December 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant human plasma gelsolin (rhu-pGSN)</keyword>
  <keyword>Severe community-acquired pneumonia (sCAP)</keyword>
  <keyword>Adjunctive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03466073/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03466073/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>6 mg/kg Rhu-pGSN Single Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care</description>
        </group>
        <group group_id="P2">
          <title>Placebo Single Dose</title>
          <description>Intravenous administration of placebo (NSS) in addition to standard of care</description>
        </group>
        <group group_id="P3">
          <title>6 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="P4">
          <title>12 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="P5">
          <title>24 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="P6">
          <title>Placebo Multiple Ascending Dose</title>
          <description>Intravenous administration of placebo (NSS) in addition to standard of care once a day for 3 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>6 mg/kg Rhu-pGSN Single Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care</description>
        </group>
        <group group_id="B2">
          <title>Placebo Single Dose</title>
          <description>Intravenous administration of placebo (NSS) in addition to standard of care</description>
        </group>
        <group group_id="B3">
          <title>6 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="B4">
          <title>12 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="B5">
          <title>24 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="B6">
          <title>Placebo Multiple Ascending Dose</title>
          <description>Intravenous administration of placebo (NSS) in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" lower_limit="35" upper_limit="81"/>
                    <measurement group_id="B2" value="64" lower_limit="62" upper_limit="66"/>
                    <measurement group_id="B3" value="69.3" lower_limit="56" upper_limit="83"/>
                    <measurement group_id="B4" value="55.3" lower_limit="45" upper_limit="70"/>
                    <measurement group_id="B5" value="40" lower_limit="22" upper_limit="66"/>
                    <measurement group_id="B6" value="64" lower_limit="39" upper_limit="78"/>
                    <measurement group_id="B7" value="58.7" lower_limit="22" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Treatment emergent adverse events were all adverse events (AEs) that occurred subsequent to enrollment. The seriousness of adverse events was judged by the site investigator.</description>
        <time_frame>0-28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg Rhu-pGSN Single Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care</description>
          </group>
          <group group_id="O2">
            <title>Placebo Single Dose</title>
            <description>Intravenous administration of placebo (NSS) in addition to standard of care</description>
          </group>
          <group group_id="O3">
            <title>6 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>24 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>Placebo Multiple Ascending Dose</title>
            <description>Intravenous administration of placebo (NSS) in addition to standard of care once a day for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Treatment emergent adverse events were all adverse events (AEs) that occurred subsequent to enrollment. The seriousness of adverse events was judged by the site investigator.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least 1 Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) (Area Under the Rhu-pGSN Concentration - Time Curve)</title>
        <description>Determine AUC 0-t area under the plasma concentration-time curve of rhu-pGSN from 0-24 hours on dosing days (estimated by subtracting pre-injection concentrations from the measured concentrations at each time point). In the single-dose arm, the subject was given only 1 dose so that data from later days were not obtained. In the multiple-dose arms, samples were obtained for each of the 3 doses.</description>
        <time_frame>On Days 0-3, specimens were obtained just prior and immediately post dose and 2, 8,12 and/or 16 , and 24 hours post completion of IV administration. In the single-dose arm, only 1 dose was given and thus no data from later days were obtained.</time_frame>
        <population>Results from participants given the 6 mg/kg rhu-pGSN dose included 4 subjects in the single-dose arm (samples from 1 subject were lost and 1 subject was withdrawn from the study) and from all 6 patients in the multiple-dose arm given this dose, yielding 10 patients for Dose 1. Only 6 patients were studied on Doses 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg Rhu-pGSN</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care (single dose and multiple doses once a day for 3 consecutive days)</description>
          </group>
          <group group_id="O2">
            <title>12 mg/kg Rhu-pGSN</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>24 mg/kg Rhu-pGSN</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) (Area Under the Rhu-pGSN Concentration - Time Curve)</title>
          <description>Determine AUC 0-t area under the plasma concentration-time curve of rhu-pGSN from 0-24 hours on dosing days (estimated by subtracting pre-injection concentrations from the measured concentrations at each time point). In the single-dose arm, the subject was given only 1 dose so that data from later days were not obtained. In the multiple-dose arms, samples were obtained for each of the 3 doses.</description>
          <population>Results from participants given the 6 mg/kg rhu-pGSN dose included 4 subjects in the single-dose arm (samples from 1 subject were lost and 1 subject was withdrawn from the study) and from all 6 patients in the multiple-dose arm given this dose, yielding 10 patients for Dose 1. Only 6 patients were studied on Doses 2 and 3.</population>
          <units>µg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-t, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984.4" spread="3798.3"/>
                    <measurement group_id="O2" value="3450.1" spread="586.5"/>
                    <measurement group_id="O3" value="6911.3" spread="1914.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-t, Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674.3" spread="1062.4"/>
                    <measurement group_id="O2" value="2602.8" spread="755.3"/>
                    <measurement group_id="O3" value="1818.4" spread="4088.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-t, Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.4" spread="626.6"/>
                    <measurement group_id="O2" value="3081.8" spread="1283.5"/>
                    <measurement group_id="O3" value="4315.8" spread="3004.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) (Maximum Observed Rhu-pGSN Plasma Concentration (Cmax))</title>
        <description>Maximum observed plasma concentration (Cmax) of rhu-pGSN in a 24 hours period after intravenous administration (estimated by subtracting pre-injection concentrations from the measured concentrations at each time point). For the 6 mg/kg dose, there were 4 evaluable subjects in the single-dose arm and 6 subjects in the multiple-dose arm at this dose, for a total of 10 evaluable subjects for Dose 1.</description>
        <time_frame>On Days 0-3, specimens were obtained just prior and immediately post dose and 2, 8, 12 and/or 16, and 24 hours post completion of IV administration. In the single-dose arm, only 1 dose was given and thus no data from later days were obtained.</time_frame>
        <population>Results from participants given the 6 mg/kg rhu-pGSN dose included 4 subjects in the single-dose arm (samples from 1 subject were lost and 1 subject was withdrawn from the study) and from all 6 patients in the multiple-dose arm given this dose, yielding results from 10 patients for Dose 1.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg Rhu-pGSN</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care (single dose and multiple doses once a day for 3 consecutive days)</description>
          </group>
          <group group_id="O2">
            <title>12 mg/kg Rhu-pGSN</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>24 mg/kg Rhu-pGSN</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) (Maximum Observed Rhu-pGSN Plasma Concentration (Cmax))</title>
          <description>Maximum observed plasma concentration (Cmax) of rhu-pGSN in a 24 hours period after intravenous administration (estimated by subtracting pre-injection concentrations from the measured concentrations at each time point). For the 6 mg/kg dose, there were 4 evaluable subjects in the single-dose arm and 6 subjects in the multiple-dose arm at this dose, for a total of 10 evaluable subjects for Dose 1.</description>
          <population>Results from participants given the 6 mg/kg rhu-pGSN dose included 4 subjects in the single-dose arm (samples from 1 subject were lost and 1 subject was withdrawn from the study) and from all 6 patients in the multiple-dose arm given this dose, yielding results from 10 patients for Dose 1.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.6" spread="393.3"/>
                    <measurement group_id="O2" value="291.9" spread="38.0"/>
                    <measurement group_id="O3" value="533.9" spread="139.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.9" spread="128.4"/>
                    <measurement group_id="O2" value="292.0" spread="79.4"/>
                    <measurement group_id="O3" value="347.3" spread="274.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.9" spread="86.0"/>
                    <measurement group_id="O2" value="320.6" spread="75.4"/>
                    <measurement group_id="O3" value="498.8" spread="275.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Anti-pGSN Antibodies (Immunogenicity) at the End of Study (Day 28)</title>
        <description>Number of participants who developed antibodies against pGSN at study day 28. Patients were first tested against less stringent screening criteria: if screen-positive, a stricter confirmatory test was performed; if screen-negative, no further immunogenicity testing was done.</description>
        <time_frame>Day 28</time_frame>
        <population>In this analysis, participants receiving single or multiple doses are reported separately.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg Rhu-pGSN Single Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care</description>
          </group>
          <group group_id="O2">
            <title>Placebo Single Dose</title>
            <description>Intravenous administration of placebo (NSS) in addition to standard of care</description>
          </group>
          <group group_id="O3">
            <title>6 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O4">
            <title>12 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O5">
            <title>24 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O6">
            <title>Placebo Multiple Ascending Dose</title>
            <description>Intravenous administration of placebo (NSS) in addition to standard of care once a day for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-pGSN Antibodies (Immunogenicity) at the End of Study (Day 28)</title>
          <description>Number of participants who developed antibodies against pGSN at study day 28. Patients were first tested against less stringent screening criteria: if screen-positive, a stricter confirmatory test was performed; if screen-negative, no further immunogenicity testing was done.</description>
          <population>In this analysis, participants receiving single or multiple doses are reported separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screened, positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confirmed, positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline and Sequential Severity Scores</title>
        <description>CURB-65 (a 5 point score in which 1 point is allocated to the presence of each of the following: Confusion, Urea &gt;7 mmol/L, Respiratory rate ≥30 breaths min, Blood pressure systolic &lt;90 mmHg or diastolic ≤60 mmHg, and age ≥65 years); PSI (Pneumonia Severity Index, used to predict risk of morbidity and mortality and is classified in risk classes ranging from I to V from the lowest to highest risk as follows: Class I: PSI 0, class II: PSI 1-70, class III: PSI 71-90, class IV: PSI 91-130, class V: PSI &gt;130); SOFA (Sequential Organ Failure Assessment, measured based on 6 variables each representing an organ system scored from 0 to 4 each (normal to severe organ dysfunction/failure), and reported as the sum (range 0-24))</description>
        <time_frame>Days 0-28</time_frame>
        <population>Results are reported for the combined multiple rhu-pGSN vs. the placebo recipients with available data. One of the placebo recipients in the MAD phase died before dose completion. Since the changes were small across dosing groups, we combined the multi-dose arm in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Rhu-pGSN Multiple Ascending Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg,12 mg/kg &amp; 24mg/kg in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Combined Placebo Multiple Ascending Dose</title>
            <description>Intravenous administration of placebo (NSS) in addition to standard of care once a day for 3 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>6 mg/kg Rhu-pGSN Single Dose</title>
            <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care</description>
          </group>
          <group group_id="O4">
            <title>Placebo Single Dose</title>
            <description>Intravenous administration of placebo (NSS) in addition to standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Sequential Severity Scores</title>
          <description>CURB-65 (a 5 point score in which 1 point is allocated to the presence of each of the following: Confusion, Urea &gt;7 mmol/L, Respiratory rate ≥30 breaths min, Blood pressure systolic &lt;90 mmHg or diastolic ≤60 mmHg, and age ≥65 years); PSI (Pneumonia Severity Index, used to predict risk of morbidity and mortality and is classified in risk classes ranging from I to V from the lowest to highest risk as follows: Class I: PSI 0, class II: PSI 1-70, class III: PSI 71-90, class IV: PSI 91-130, class V: PSI &gt;130); SOFA (Sequential Organ Failure Assessment, measured based on 6 variables each representing an organ system scored from 0 to 4 each (normal to severe organ dysfunction/failure), and reported as the sum (range 0-24))</description>
          <population>Results are reported for the combined multiple rhu-pGSN vs. the placebo recipients with available data. One of the placebo recipients in the MAD phase died before dose completion. Since the changes were small across dosing groups, we combined the multi-dose arm in the analysis</population>
          <units>unitless</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CURB-65-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CURB-65 from Baseline to Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSI score-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="38" upper_limit="91"/>
                    <measurement group_id="O2" value="78" lower_limit="56" upper_limit="98"/>
                    <measurement group_id="O3" value="67.5" lower_limit="46" upper_limit="119"/>
                    <measurement group_id="O4" value="69" lower_limit="62" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in PSI score from Baseline to Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-10" upper_limit="1"/>
                    <measurement group_id="O2" value="-5" lower_limit="-10" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOFA score-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O4" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SOFA score from Baseline to Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-3" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O3" value="-1" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O4" value="-2" lower_limit="-2" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>6 mg/kg Rhu-pGSN Single Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care</description>
        </group>
        <group group_id="E2">
          <title>Placebo Single Dose</title>
          <description>Intravenous administration of placebo (NSS) in addition to standard of care</description>
        </group>
        <group group_id="E3">
          <title>6 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="E4">
          <title>12 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="E5">
          <title>24 mg/kg Rhu-pGSN Multiple Ascending Dose</title>
          <description>Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg in addition to standard of care once a day for 3 consecutive days</description>
        </group>
        <group group_id="E6">
          <title>Placebo Multiple Ascending Dose</title>
          <description>Intravenous administration of placebo (NSS) in addition to standard of care once a day for 3 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark DiNubile MD</name_or_title>
      <organization>BioAegis Therapeutics Inc.</organization>
      <phone>609-706-5866</phone>
      <email>mdinubile@bioaegistx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

